[1]CurrentPatentAssignee:NUOWOSIDAPHARMACEUTICAL;NOVOSTARPHARMACEUTICALS-CN110776492,2020,ALocationinpatent:Paragraph0139-0141;0147-0151
Title: Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects.
Journal: Antimicrobial agents and chemotherapy 20141001
Title: Simultaneous determination of morinidazole, its N-oxide, sulfate, and diastereoisomeric N(+)-glucuronides in human plasma by liquid chromatography-tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20121101
Title: Simultaneous quantification of metronidazole, tinidazole, ornidazole and morinidazole in human saliva.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120615
Title: Metabolism and pharmacokinetics of morinidazole in humans: identification of diastereoisomeric morpholine N+-glucuronides catalyzed by UDP glucuronosyltransferase 1A9.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120301
Title: [Enantioselective determinination of R-warfarin/S-warfarin in human plasma using liquid chromatography-tandem mass spectrometry and its application in a drug-drug interaction study].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20120101
Title: Investigation of the effects of 24 bio-matrices on the LC-MS/MS analysis of morinidazole.
Journal: Talanta 20100115
Title: Zhong K, et al. Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearanceof the conjugated metabolites. Antimicrob Agents Chemother. 2014 Jul;58(7):4153-61.
Title: Kong F, et al. Increased Plasma Exposures of Conjugated Metabolites of Morinidazole in Renal Failure Patients: A Critical Role of Uremic Toxins. Drug Metab Dispos. 2017 Jun;45(6):593-603.
Title: Lu Aifeng, et al. Application of α-(morpholine-1-yl)methyl-2-methyl-nitroimidazole-1-ethanol as anti-trichomonal agent and amebacide: China, CN1981764[P 2007-06-20.
